Roth Capital set a $9.00 target price on Matinas BioPharma Holdings Inc (NASDAQ:MTNB) in a research note issued to investors on Thursday morning. The firm currently has a buy rating on the stock.

Separately, Maxim Group set a $6.00 price objective on Matinas BioPharma Holdings and gave the stock a buy rating in a report on Tuesday, May 16th.

Matinas BioPharma Holdings (NASDAQ:MTNB) traded up 3.03% during mid-day trading on Thursday, reaching $1.36. 112,583 shares of the company’s stock were exchanged. The company’s market cap is $125.08 million. Matinas BioPharma Holdings has a 52-week low of $0.67 and a 52-week high of $3.99. The stock has a 50-day moving average price of $1.46 and a 200 day moving average price of $2.54.

Matinas BioPharma Holdings (NASDAQ:MTNB) last issued its quarterly earnings data on Tuesday, August 8th. The company reported ($0.04) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. Matinas BioPharma Holdings had a negative return on equity of 1,227.85% and a negative net margin of 30,034.20%. The company had revenue of $0.05 million during the quarter, compared to analyst estimates of $0.02 million. Equities analysts predict that Matinas BioPharma Holdings will post ($0.26) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Matinas BioPharma Holdings Inc (MTNB) Given a $9.00 Price Target at Roth Capital” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.thecerbatgem.com/2017/08/14/matinas-biopharma-holdings-inc-mtnb-given-a-9-00-price-target-at-roth-capital.html.

Several hedge funds have recently modified their holdings of MTNB. Vanguard Group Inc. purchased a new stake in shares of Matinas BioPharma Holdings during the second quarter valued at approximately $4,135,000. IFP Advisors Inc purchased a new stake in shares of Matinas BioPharma Holdings during the second quarter valued at approximately $1,183,000. Raymond James Financial Services Advisors Inc. purchased a new stake in shares of Matinas BioPharma Holdings during the first quarter valued at approximately $1,781,000. Northern Trust Corp purchased a new stake in shares of Matinas BioPharma Holdings during the second quarter valued at approximately $980,000. Finally, Alliance Wealth Management Group purchased a new stake in shares of Matinas BioPharma Holdings during the first quarter valued at approximately $1,162,000.

About Matinas BioPharma Holdings

Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections.

Receive News & Stock Ratings for Matinas BioPharma Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma Holdings Inc and related stocks with our FREE daily email newsletter.